07:00 , Jul 13, 2015 |  BC Week In Review  |  Company News

Endo, Braeburn deal

Braeburn purchased Endo’s EN3342, a six-month polyurethane implant to deliver risperidone, and the associated implant technology. EN3342 is slated to begin a Phase III trial in schizophrenia by year end. The companies declined to disclose...